MeSH tree: D02.925.200
Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, followed by radiation and chemotherapy. The prognosis is poor even with treatment. A challenge in ...
Feb 20, 2025
0
24
In spite of intensive research, glioblastoma remains one of the most lethal types of brain cancer. Temozolomide (TMZ) is used as the front-line medicine in its treatment.
Dec 19, 2024
0
21
A simple change to the chemotherapy regimen for people with Hodgkin lymphoma could reduce the long-term health impacts that can result from treatment, according to researchers in Cambridge. The findings could lead to the ...
Dec 12, 2024
0
31
Both radiation and temozolomide, a generic chemotherapy treatment in pill form, have meaningful single-modality anti-tumor activity against slow-growing, low-grade gliomas. The randomized phase 3 trial E3F05 by the ECOG-ACRIN ...
Nov 25, 2024
0
16
A study led by Dr. Monika E. Hegi, MD, Ph.D. and European Organization for Research and Treatment of Cancer (EORTC) headquarters team (Felix Oppong Msc, Dr. Thierry Gorlia, Ph.D.) reveals that elderly glioblastoma patients ...
Oct 9, 2024
0
19
Glioblastoma is one of the most serious brain diseases known. More than 45% of brain cancers are gliomas. Only half of glioblastoma patients respond to the FDA-approved chemotherapy temozolomide (TMZ). Even for those patients, ...
Sep 30, 2024
0
34
A new approach to treating the most malignant type of brain cancer—glioblastoma—has shown strong promise in pre-clinical settings, raising hopes of increasing current average survival rates beyond 18 months.
Jul 9, 2024
0
42
Glioblastoma multiforme (GBM) is among the most aggressive forms of brain tumors, with few effective treatment options and a bleak prognosis. The current standard of care (SOC), known as the STUPP regimen, includes surgical ...
Jun 12, 2024
0
41
Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92% of evaluable patients treated with INB-200 exceeded a median ...
Jun 5, 2024
0
28
For many patients with a deadly type of brain cancer called glioblastoma, chemotherapy resistance is a big problem.
May 20, 2024
0
43
